基质金属蛋白酶抑制剂的研究进展  

Progress on the research of matrix metalloproteinase inhibitors

作　　者：马林玲 孟照辉[1] Ma Linling;Meng Zhaohui(Department of Laboratory of Molecular Cardiology,the First Affiliated Hospital of Kunming Medical University,Kunming 650032,Chin)

机构地区：[1]昆明医科大学第一附属医院心内科分子心血管研究室,云南昆明650032

出　　处：《临床医学》2018年第7期119-122,共4页Clinical Medicine

基　　金：国家自然科学基金(81160025);云南省科技厅联合重点项目(30860278)~~

摘　　要：基质金属蛋白酶(MMPs)是钙锌依赖的蛋白水解酶,其主要作用为组织重塑及细胞外基质的降解。MMPs在各种病理条件下扮演着重要的角色,如动脉粥样硬化的形成,肿瘤的侵袭及转移等,目前研究表明基质金属蛋白酶抑制剂(MMPIs)能通过抑制MMPs的活性在肿瘤及类风湿性关节炎治疗中发挥作用,然而现有抑制剂特异性差,抑制作用不明显,不良反应大而无法安全应用与临床,因此新的抑制剂研究有待进一步探讨。Matrix metalloproteinase （MMPs） is a calcium zinc dependent proteolytic enzyme, which plays a major role in tissue remodeling and extracellular matrix degradation. MMPs play an impor- tant role in various pathological conditions, such as atherosclerosis, tumor invasion and metastasis. At present, the research shows that matrix metalloproteinase inhibitor （MMPIs） can play a role in the treat- ment of tumor and rheumatoid arthritis by inhibiting the activity of MMPs. However, the existing inhibi- tors have poor specificity, no obvious inhibition and many adverse reactions, which cannot be used safely in clinical applications, so new inhibitors need to be further studied.

关 键 词：基质金属蛋白酶 基质金属蛋白酶抑制剂 心血管疾病 类风湿性关节炎 

分 类 号：R97[医药卫生—药品]